Mirion Technologies, Inc. (MIR)
| Market Cap | 4.76B +54.3% |
| Revenue (ttm) | 981.00M +12.7% |
| Net Income | 25.10M |
| EPS | 0.10 |
| Shares Out | 250.42M |
| PE Ratio | 194.13 |
| Forward PE | 34.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,114,330 |
| Open | 19.86 |
| Previous Close | 19.75 |
| Day's Range | 18.86 - 19.86 |
| 52-Week Range | 16.06 - 30.28 |
| Beta | 1.07 |
| Analysts | Strong Buy |
| Price Target | 27.00 (+42.18%) |
| Earnings Date | Apr 28, 2026 |
About MIR
Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in North America, Europe, and the Asia Pacific. It operates in two segments, Medical, and Nuclear & Safety. The Medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medi... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for MIR stock is "Strong Buy." The 12-month stock price target is $27.0, which is an increase of 42.18% from the latest price.
News
Mirion price target lowered to $28 from $29 at Evercore ISI
Evercore ISI lowered the firm’s price target on Mirion (MIR) to $28 from $29 and keeps an Outperform rating on the shares.
Mirion price target lowered to $28 from $29 at Citi
Citi lowered the firm’s price target on Mirion (MIR) to $28 from $29 and keeps a Buy rating on the shares.
Mirion Technologies Earnings Call Transcript: Q1 2026
Orders and backlog surged on strong nuclear and medical segment growth, with Paragon and Certrec acquisitions driving early synergies. Revenue and adjusted EBITDA rose year-over-year, and guidance remains confident for 2026, with margin expansion and robust nuclear demand expected.
Mirion reports Q1 adjusted EPS 10c, consensus 9c
Reports Q1 revenue $257.6M, consensus $244.77M. “Our first quarter performance showcased substantial orders growth led by nuclear power demand and as-expected Adjusted EBITDA performance and margins,”...
Mirion Announces First Quarter 2026 Financial Results
ATLANTA--(BUSINESS WIRE)--Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and re...
Mirion Announces Earnings Release and Conference Call Date for First Quarter 2026
ATLANTA--(BUSINESS WIRE)--Mirion (NYSE: MIR) announced today that it will release financial results for first quarter 2026 after market close on Tuesday, April 28, 2026. Following the news release, th...
Mirion price target lowered to $28 from $29 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Mirion (MIR) to $28 from $29 and keeps a Buy rating on the shares as part of a broader research note previewing
Mirion price target lowered to $26 from $29 at Baird
Baird analyst Quinn Fredrickson lowered the firm’s price target on Mirion (MIR) to $26 from $29 and keeps an Outperform rating on the shares. The firm remains positive on the
Mirion price target lowered to $27 from $30 at JPMorgan
JPMorgan lowered the firm’s price target on Mirion (MIR) to $27 from $30 and keeps an Overweight rating on the shares. The firm updated models in the North American small-cap
Mirion price target lowered to $27 from $29 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Mirion (MIR) to $27 from $29 and keeps an Equal Weight rating on the shares. The firm is updating and rolling forward
Mirion price target lowered to $30 from $33 at JPMorgan
JPMorgan analyst Tomohiko Sano lowered the firm’s price target on Mirion (MIR) to $30 from $33 and keeps an Overweight rating on the shares. The firm says that as macro
Mirion Technologies Transcript: Citi's Global Industrial Tech & Mobility Conference 2026
Nuclear power drives nearly half of revenue, with strong growth in SMRs, international projects, and recurring installed base business. Margin expansion, robust backlog, and AI-driven productivity are key themes, while medical and nuclear medicine segments show continued growth potential.
Mirion price target lowered to $29 from $30 at Baird
Baird lowered the firm’s price target on Mirion (MIR) to $29 from $30 and keeps an Outperform rating on the shares. The firm updated its model following mixed Q4 results
Mirion to Present at Citi's 2026 Global Industrial Tech and Mobility Conference
ATLANTA--(BUSINESS WIRE)--Mirion (NYSE: MIR) announced today that Chairman and Chief Executive Officer, Thomas Logan, and Chief Financial Officer and Medical Group President, Brian Schopfer, will pres...
Mirion price target lowered to $29 from $33 at Goldman Sachs, says buy the dip
Goldman Sachs lowered the firm’s price target on Mirion (MIR) to $29 from $33 and keeps a Buy rating on the shares. Mirion posted Q4 adjusted EBITDA of $77.6M, driven
Mirion price target lowered to $29 from $32 at Citi
Citi lowered the firm’s price target on Mirion (MIR) to $29 from $32 and keeps a Buy rating on the shares.
Mirion Technologies Earnings Call Transcript: Q4 2025
Record orders and strong growth in nuclear power and medicine drove 2025 results, with revenue up 7.5% and Adjusted EBITDA up 12%. 2026 guidance calls for 22%-24% revenue growth, margin expansion, and robust free cash flow, supported by recent acquisitions and a growing project pipeline.
Mirion announces executive appointments to accelerate strategic growth
Mirion (MIR) announced three new leadership appointments. Tighe Smith has been promoted to the newly created role of chief nuclear officer to lead the company’s global nuclear strategy. Shelia Webb
Mirion Announces Executive Appointments to Accelerate Strategic Growth and Market Focus
ATLANTA--(BUSINESS WIRE)--Mirion (NYSE: MIR), a global leader in radiation detection, measurement, analysis and monitoring solutions for the nuclear, medical, defense and research end markets, today a...
Mirion reports Q4 adjusted EPS 15c, consensus 16c
Reports Q4 revenue $277.4M, consensus $281.17M. “Mirion (MIR) concluded another successful year, highlighted by record orders, strong tailwinds from key strategic end-markets, and a broadening nuclear...
Mirion Announces Fourth Quarter and Full Year 2025 Financial Results; Provides Full Year 2026 Guidance
ATLANTA--(BUSINESS WIRE)--Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and re...
Mirion initiated with an Equal Weight at Morgan Stanley
Morgan Stanley initiated coverage of Mirion (MIR) with an Equal Weight rating and $29 price target While Mirion will benefit from additional global nuclear power generation capacity driven by data
Mirion Announces Earnings Release and Conference Call Date for Fourth Quarter and Full Year 2025
ATLANTA--(BUSINESS WIRE)--Mirion (NYSE: MIR) announced today that it will release financial results for fourth quarter and full year 2025 after market close on Tuesday, February 10, 2026. Following th...
Mirion
Citi analyst Andrew Kaplowitz lowered the firm’s price target on Mirion (MIR) to $32 from $33 and keeps a Buy rating on the shares. The firm adjusted targets in the